Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today.
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval in Type 1 diabetes and hypertrophic cardiomyopathy, but new data and ongoing trials offer near-term catalysts. Novo Nordisk partnership on LX9851 and improved pilavapadin data provide financial support and partnership credibility, helping LXRX regain Nasdaq compliance.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate Communications Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Scott Coiante - Senior VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Lexicon Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year ago.
